# Docetaxel, Cisplatin, Pegfilgrastim, and Erlotinib Hydrochloride in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

> **NCT01557959** · PHASE2 · COMPLETED · sponsor: **Wake Forest University Health Sciences** · enrollment: 45 (actual)

## Conditions studied

- Adenocarcinoma of the Lung
- Adenosquamous Cell Lung Cancer
- Bronchoalveolar Cell Lung Cancer
- Large Cell Lung Cancer
- Non-small Cell Lung Cancer
- Recurrent Non-small Cell Lung Cancer
- Squamous Cell Lung Cancer
- Stage IIIB Non-small Cell Lung Cancer
- Stage IV Non-small Cell Lung Cancer

## Interventions

- **DRUG:** cisplatin
- **BIOLOGICAL:** pegfilgrastim
- **DRUG:** erlotinib hydrochloride
- **OTHER:** laboratory biomarker analysis
- **GENETIC:** polymorphism analysis
- **OTHER:** pharmacogenomic studies
- **GENETIC:** genetic linkage analysis
- **DRUG:** docetaxel

## Key facts

- **NCT ID:** NCT01557959
- **Lead sponsor:** Wake Forest University Health Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07
- **Primary completion:** 2011-02
- **Final completion:** 2011-02
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2018-06-29

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01557959

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01557959, "Docetaxel, Cisplatin, Pegfilgrastim, and Erlotinib Hydrochloride in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01557959. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*